Women on blockbuster weight loss drugs warned to use effective contraception
Pregnant women should not take weight loss drugs, the UK's medicines regulator warned amid concerns that people are using the so-called 'skinny jabs' in unsafe ways.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby.
'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said.
Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said.
Related
Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment
One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD).
'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement.
'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added.
Related
France won't pay for weight loss drug Wegovy. What about other European countries?
In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro.
The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity.
Related
Why are 1 in 10 French women still smoking during pregnancy despite the health risks?
But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor.
'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement.
'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity (NCT06972992) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Hockey player 'in limbo' after head struck by ball
"I understand there is an element of risk in hockey, but surely a brain injury must trigger some help?" Claerwen Render, 42, loved sports but her life changed when she was hit on the forehead by a hockey ball five years ago. Advertisement The mother-of-three has suffered daily migraines and fatigue since and has seen her income halve after giving up her role as a member of a secondary school's senior leadership team. But after being refused an insurance payout through her sport's governing body, she has been left questioning if affiliation payments are worth it. Hoci Cymru said it had developed their approach to head injuries but that more needed to happen to explain the limitations of insurance cover. Mrs Render was playing for Clwb Hoci Rhuthun in Denbighshire in November 2019 when she was caught on the temple by a ball struck by an opposing player. Advertisement Bleeding badly, she was taken by ambulance to the nearest A&E department. Over the next few months she tried to return to the classroom as a maths teacher, but struggled to cope. "I'm not getting half my old life back. I'm just in limbo, in pain," said Mrs Render. "I can't do anything. It really affects my sleep. I've taken time off work but no amount of rest gets rid of my symptoms. It's debilitating. "I can't do normal things like before. I can't enjoy going to the kids' activities. If I stay I suffer, or I'll go to work in more pain and I have to go to bed." Advertisement Nine months after the incident, Mrs Render, from Denbigh, made an insurance claim through her Hoci Cymru membership but said her application did not trigger any benefits. She now works four mornings a week having been diagnosed with post-concussion syndrome. "Why have I paid 15 years of affiliation and insurance? It was for something like this," said Mrs Render. "I understand there is an element of risk, but surely a brain injury must trigger something? Are we just paying into a bottomless pit? "I'm just disappointed that I'm not compensated for loss of earnings, the future of my kids, everything." Advertisement One sports lawyer said few players were fully aware of the level of cover they have for head injuries. "No-one signs up to play these sports to get permanent and progressive brain damage and a very high number of sports men and women, we believe, have that," said Richard Boardman, from law firm Rylands Garth. Claerwen Render had to give up her role on her secondary school's senior leadership team after being injured [BBC] "It is critical that all grassroots players know about the risks involved in collision sports, and whether they are covered for brain injuries," Mr Boardman added. Colin Morris from brain injury charity Headway, stressed the health and social benefits of sports, including brain health, but also said players needed to be aware of how insurance cover works. Advertisement "It is something that governing bodies and insurers need to be transparent with and really convey to people what circumstances they wouldn't be covered. "So people can take out further insurance if they need to, protection against loss of income for example," he said. Hoci Cymru's concussion policy was first introduced in 2021. Its chief executive, Paul Whapham, said they could not comment on individual insurance cases but acknowledged the "very real impact" Mrs Render's injury had and took her concerns "seriously". "This situation highlights the importance of clear communication and transparency around insurance coverage," said Mr Whapham. Advertisement He added Hoci Cymru's approach to head injuries had developed but there was "always more" to be done so players "understand the extent and limitations of cover provided through affiliation". "We are committed to working with our insurers, our clubs and partners to ensure that policies are clear, fair and supportive of our players' wellbeing," Mr Whapham said.
Business Insider
4 hours ago
- Business Insider
Eli Lilly's obesity drug sales rise in India, Bloomberg reports
Eli Lilly (LLY) increased its sale of Mounjaro, its weight-loss and diabetes drug, by 60% in India in May from April, Satviki Sanjay of Bloomberg reports. The company sold $1.5M worth of injections last month, Bloomberg said, citing market analysis firm Pharmarack Technologies. 'The patient number may have actually doubled' in May from April Pharmarack Vice President Sheetal Sapale told Bloomberg News. The demand is rising gradually and is expected to continue. Confident Investing Starts Here:
